Zogenix, Inc.

Please stand by. The conference call will begin momentarily. We thank you for your patience and ask that you please remain on the line. Once again, please stand by. The conference call will begin momentarily. Greetings, and welcome to the Zojenix, Inc. First Quarter 2021 Financial Results Conference Call. During the presentation, all participants will be in a listen-only mode. Afterwards, we will conduct a question and answer session. At that time, if you have a question, please press the 1 followed by the 4 on your telephone. If at any time during the conference you need to reach an operator, please press star 0. As a reminder, this conference is being recorded today. Thursday, May 6th, 2021. I'd now like to turn the conference over to Brian Ritchie of LifeSci Advisors. Please go ahead.

Thank you, Operator, and thank you all for joining us this afternoon. With me on today's call are Chief Executive Officer, Dr. Stephen Farr, Chief Commercial Officer, Ashish Sagrolikar, and Chief Financial Officer, Michael Smith. This afternoon, Zogenix issued a news release providing a business update and announcing financial results for the first quarter ended March 31st, 2021. Please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We caution listeners that during this call, Sogenix management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Zogenix's press release issued today and the company's SEC filings, including in the annual report on Form 10-K and subsequent filings. This conference call also contains time-sensitive information that is accurate only as of the date of this live broadcast, May 6, 2021. Zigenix undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. Now, I'd like to turn the call over to Steve.

Thank you, Brian, and good afternoon to everyone. I'm very pleased to be here with you today to provide updates on what has been another exciting and productive quarter for Zigenix. Despite the operational challenges brought on by the ongoing pandemic, our commercial launches of Fintepla for Dravet syndrome in the United States and Europe continue to progress well. As Ashish will describe shortly, we are very encouraged by the steady growth in adoption by both existing and new prescribing physicians and patients, and by the continuing positive dialogue with commercial and government payers. With more physicians gaining experience with Fintepla and more patients reaching that effective dose, we see a marked increase in the type of prescribing base and a beneficial impact on dosing trends. We are now beginning to see an increase in the ability of our field-based teams to travel and meet with physicians and other healthcare professionals. As a result, we are looking forward to the positive impact this will have on our commercial activities and other aspects of our business. I'll now turn the call over to Ashish for further details on how our launches are progressing in the US and in Europe. Ashish, over to you.